BioSpace News Archive

InnoCare Pharma, a commercial-stage biotech company, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for the Company’s B-cell lymphoma-2 inhibitor, ICP-248.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has received Qualified Infectious Disease Product and Fast Track designation from the US FDA for NRX-101 in the treatment of complicated urinary tract infections and pyelonephritis.

EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single-cell technologies, announced the recent publication of the STIC CTC trial data demonstrating the clinical utility of CTC count as an independent prognostic factor in advanced breast cancer.

Revive Therapeutics Ltd. announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre, an agency of the Canadian Department of National Defence.

NightHawk Biosciences, an integrated contract development and manufacturing organization, announced its Scorpius BioManufacturing subsidiary has been awarded a project to support a preclinical program for a U.S. based biotech company.

Horizon Therapeutics plc, now part of Amgen, announced that on December 15, 2023, Health Canada approved UPLIZNA® (inebilizumab for injection) as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.

IMVARIA Inc. announced that the U.S. Food and Drug Administration has granted marketing authorization for the use of Fibresolve, a digital biomarker solution that uses artificial intelligence to guide safe, non-invasive diagnosis of lung fibrosis with a focus on idiopathic pulmonary fibrosis.

Mirum Pharmaceuticals, Inc., announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical development, clinical operations, and safety programs for Mirum’s pipeline of programs addressing rare diseases.

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on POSLUMA® (flotufolastat F 18) injection (formerly known as 18F-rhPSMA-7.3) at the upcoming ASCO GU 2024 Genitourinary Cancers Symposium (ASCO GU).